Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 12, 2013, Pages 1274-1282

  Coplan, Paul M ^a,b   Kale, Hrishikesh ^a   Sandstrom, Lauren ^a   Landau, Craig ^a   Chilcoat, Howard D ^a,c  

^a PURDUE PHARMA L P   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Abuse deterrence; Heroin; Opioid abuse; Oxycodone; Patient outcomes; Pharmacoepidemiology; Poison centers

Indexed keywords

DIAMORPHINE; OXYCODONE;

ADVERSE OUTCOME; ARTICLE; DRUG FORMULATION; DRUG MISUSE; EDUCATIONAL STATUS; HUMAN; OPIATE ADDICTION; OUTCOME ASSESSMENT; PHYSICAL CHEMISTRY; POISON CENTER; PRESCRIPTION; PRIORITY JOURNAL; SUICIDE; THERAPEUTIC ERROR;

ABUSE DETERRENCE; HEROIN; OPIOID ABUSE; OXYCODONE; PATIENT OUTCOMES; PHARMACOEPIDEMIOLOGY; POISON CENTERS;

ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; HEROIN; HUMANS; LOGISTIC MODELS; MODELS, STRUCTURAL; OPIOID-RELATED DISORDERS; OXYCODONE; POISON CONTROL CENTERS; PRESCRIPTION DRUG MISUSE; UNITED STATES;

EID: 84888437924     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3522     Document Type: Article

References (39)

1. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013; 309(7): 657-659.
2. Birnbaum HG, White AG, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain 2006; 22: 667-676.
3. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363: 1981-1983.
4. White AG, Birnbaum, HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005; 11: 469-479.
5. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10(2): 113-130.
6. American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009; 57(8): 1331-1346.
7. Department of Veterans' Affairs/Department of Defense (VA/DoD). Clinical practice guideline: management of opioid therapy for chronic pain, 2010.
8. National Opioid Use Guideline Group (NOUGG). Canadian guideline for safe and effective use of opioids for chronic non-cancer pain, 2010.
9. American Academy of Pain Medicine. Use of opioids for the treatment of chronic pain. March 2013. Available at: http://www.painmed.org/files/use-of-opioids-for-the-treatment-of-chronic-pain.pdf
10. FDA News Release. FDA introduces new safety measures for extended-release and long-acting opioid medications. July 9, 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm [30 March 2013].
11. Raffa RB, Pergolizzi JV. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70(13): 1657-1675.
12. Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse 2011; 37: 205-217.
13. FDA Guidance for Industry. Abuse-deterrent opioids - evaluation and labeling. Released on Jan. 9, 2013. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
14. National Drug Intelligence Center. OxyContin diversion and abuse. January 2001. http://www.justice.gov/archive/ndic/pubs/651/abuse.htm [23 February 2012].
15. Hays L, Kirsh KL, Passik SD. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw 2003; 1: 423-428.
16. Hays LR. A profile of OxyContin addiction. J Addict Dis 2004; 23(4): 1-9.
17. Butler SF, Black RA, Grimes Serrano JM, Wood ME, Budman SH. Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns and functional severity. J Opioid Manag 2010; 6(4): 239-252.
18. OxyContin [full prescribing information]. Stamford, CT: Purdue Pharma L.P., 2012. http://app.purduepharma.com/xmlpublishing/pi.aspx?id=o [25 January 2013].
19. Centers for Disease Control and Prevention (CDC). CDC grand rounds: prescription drug overdoses - a U.S. epidemic. Morb Mortal Wkly Rep 2012: 61(01); 10-13. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6101a3.htm?s_cid=mm6101a3_w [12 December 2012].
20. Cone EJ, Fant RV, Rohay JM, et al. Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol 2003; 27: 57-67.
21. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009; 181: 891-896.
22. Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011; 8: 29-45.
23. TM): a real-time, product-specific public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008; 17: 1142-1154.
24. Katz N, Fernandez K, Chang A, Benoit C, Butler SF. Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain 2008; 24(6): 528-535.
25. Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother 2006; 20(2): 5-13.
26. Cone EJ, Giordano J, Weingarten B. An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug and Alcohol Depend 2013; 131(1-2): 100-105.
27. th Annual Meeting, Palm Springs, CA, USA. June 2012.
28. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013; 14(4): 351-358.
29. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 367 2012; 2: 187-189.
30. Dasgupta N, Davis J, Jonsson Funk M, Dart R. Using poison center exposure calls to predict methadone poisoning deaths. PLoS One 2012; 7(7): e41181.
31. Centers for Disease Control and Prevention (CDC). CDC fact sheet: using the National Poisoning Data System for public health surveillance - a collaborative effort of the Centers for Disease Control and Prevention and the American Association of Poison Control Centers. Department of Health and Human Services. July 2005. www.cdc.gov/nceh/hsb/chemicals/pdfs/npds.pdf. [13 February 2013].
32. th Annual Report. Clin Toxicol 2012; 50: 911-1164.
33. American Association of Poison Control Centers. National Poison Data System (NPDS) Data Dictionary. 2012; (2012.9.21): 24-41.
34. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995; 6(4): 356-365.
35. Rothman KJ, Greenland S, Lash TL. Modern epidemiology (3rd edn). Lippincott, Williams & Wilkins: Philadelphia (PA), 2008; 410.
36. Bronstein AC, Spyker DA, Cantilena LR Jr, Rumack BH, Dart RC. 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila) 2012; 50(10): 911-1164.
37. Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med 2012; 13(3): 434-42.
38. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011; 12(5): 747-54.
39. Office of National Control Policy (2011). Epidemic: responding to America's prescription drug abuse crisis. Available at: http://www.whitehouse.gov/ondcp/prescription-drug-abuse [30 March 2013].